LONDON - Aptamer Group PLC, a UK-based biotechnology firm, has experienced a shift in its shareholder structure. On Monday, Dowgate Capital Limited, operating under Dowgate Group Limited, decreased its holding in the company, crossing a significant threshold that necessitated a regulatory notification.
The transaction, which occurred on December 16, 2024, brought Dowgate Capital Limited's stake in Aptamer Group to 4.9% from a previous holding of 6.14%. As a result of this change, Dowgate Capital Limited now holds 97,446,568 voting rights within the company. The notification to Aptamer Group PLC was made on the following day, December 17.
The disclosure of this information is in compliance with the Transparency Directive's regulatory framework, which requires investors to notify listed companies of changes in major shareholdings. This transparency is crucial for maintaining fair and efficient markets, giving investors insight into significant changes in company ownership.
Aptamer Group PLC, with its ISIN code GB00BNRRP542, has not commented on the reasons behind Dowgate Capital Limited's reduction of its stake. The details of the transaction were made public through RNS, the news service of the London Stock Exchange (LON:LSEG), which is authorized by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom (TADAWUL:4280).
The announcement is based on a press release statement and provides a snapshot of the current ownership structure of Aptamer Group PLC, which may be of interest to investors and market watchers. This change in shareholding percentage is a factual event without any indication of the strategic implications for Aptamer Group PLC or the intentions of Dowgate Capital Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.